Skip main navigation

Home > Search Results

Main contents starts here

Search Results

41 - 60 of about 337

Total 337 documents found.

  •  
  • Approach to Accident Prevention
  • Takeda prepares "Policies on Accident Prevention" every fiscal year, based upon which each business unit establishes a concrete plan involving the adoption of approaches to both "hardware" and "software" for accident prevention.
  • Basic Principles on the Environment
  • Basic Principles on the Environment: 1.Overall Policy: Give serious consideration to the impact on the environment in every aspect of corporate activities, including R&D, production, distribution, marketing, procurement and clerical works, and make the best efforts to conserve and improve the environment.
  • Corporate Governance
  • Takeda strives to strengthen internal control, including thorough compliance, as well as promoting the establishment of a system allowing the creation of a healthy and transparent environment for quick decision-making in order to establish a management framework befitting a "world-class pharmaceutical company with Japanese origine," which operates business worldwide .
  • Annual Reports
  • A report presenting Takeda’s corporate pilosophy and annual business performance
  • 88 Corporate Governance Policy toward Corporate Governance Fundamental Policy and Structure Management Structure Takeda's management mission is "we strive toward better health for individuals and progress in medicine by developing superior pharmaceutical products." In line with this mission, Takeda is working to establish a management framework befitting a world-class pharmaceutical company that operates globally. We are strengthening internal control, including rigorous compliance, and establishing a structure to facilitate rapid decisionmaking that is sound and transparent. Through these efforts, we will further enhance our corporate governance, thereby maximizing the corporate value. The Board of Directors determines fundamental policies for the Takeda Group and reaches decisions concerning the operations of Takeda. Management and business operations are then conducted in accordance with these decisions. In fiscal 2009, Takeda established the positions of Chief Scientific Officer (CSO), Executive Vice Pre
  • 64 Fundamental Stance regarding the Preservation of Biodiversity Kyoto Herbal Garden The Earth plays host to as many as 30 million species of living things. But this number is falling at an alarming rate. According to the U.N. Millennium Ecosystem Assessment, which was completed in 2005, the current rate of extinctions is about 1,000 times greater than the extinction rate in ancient times based on fossil records. Moreover, many scientists believe a further increase of more than 10 times in the extinction rate is inevitable. The U.N. has declared 2010 to be the International Year of Biodiversity. In this year, the 10th Conference of the Parties to the Convention on Biological Diversity (COP10) will take place in Nagoya, Japan. As a company engaged in businesses that protect life, Takeda has a long history of commitment to protecting biodiversity. We have contributed in many ways over the years, particularly through the Kyoto Herbal Garden, which grows many plants that are on the verge of extinction. As a phar
  • - 1 - SUMMARY OF FINANCIAL STATEMENTS (CONSOLIDATED) Financial Results for the Fiscal Year Ended March 31, 2010 May 12, 2010 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: http://www.takeda.co.jp Representative: Yasuchika Hasegawa, President & CEO Contact: Hiroshi Ohtsuki, Corporate Officer, Senior Vice President, Corporate Communications Department Telephone: +81-3-3278-2037 Scheduled date of annual general meeting of shareholders: June 25, 2010 Scheduled date of securities report submission: June 25, 2010 Scheduled date of dividend payment commencement: June 28, 2010 (Millions of yen, rounded to the nearest million) 1. Consolidated Results for Fiscal 2009 (April 1, 2009-March 31, 2010) (1) Consolidated Operating Results (Percentage figures represent changes from same period of previous
  • 58 Corporate Governance Policy toward Corporate Governance Fundamental Policy and Structure Management Structure Takeda's management mission is "we strive toward better health for individuals and progress in medicine by developing superior pharmaceutical products." In line with this mission, Takeda is working to establish a management framework befitting a world-class pharmaceutical company that operates globally. We are strengthening internal control, including rigorous compliance, and establishing a structure to facilitate rapid decisionmaking that is sound and transparent. Through these efforts, we will further enhance our corporate governance, thereby maximizing the corporate value. The Board of Directors determines fundamental policies for the Takeda Group and reaches decisions concerning the operations of Takeda. Management and business operations are then conducted in accordance with these decisions. In fiscal 2009, Takeda established the positions of Chief Scientific Officer (CSO), Executive Vice Pre
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2009 - 4 - [Qualitative Information and Financial Statements] 1. Results of Operations (1) Analysis of Operation Results 1) Introduction Whole of the pharmaceutical industry has tendency to face a number of challenges, such as stagnation in creating breakthrough novel drugs due to the difficulties of translating new innovations to products in the marketplace, and increasingly strict criteria for the approval of new drugs in advanced countries. Drastic changes in the healthcare systems are underway in many countries, by which it is anticipated that the pharmaceutical industry will be considerably affected. First of all, in the U.S., a bill of healthcare reform which aims to increase the ratio of the insured population was passed. Under the bill, pharmaceutical companies are requested to bear the burden of some portion of funds in order to finance the expansion of available health insurance by increase of the number of po
  • 36 Preventing accidents and protecting the environment with a broad array of programs Accident Prevention Initiatives Accident Prevention Training at the Hikari Plant Takeda establishes the "Policies on Accident Prevention" in each fiscal year. Each business site establishes an action plan based on the policies for preventive measures that cover both facilities and employee skills. For facilities, we have a rigorous management program that includes a maintenance plan for aging equipment. To prevent fires and other accidents, we have safety measures concerning static electricity and flammable substances. Static electricity can create explosions and fires by igniting flammable gases and dust in facilities. This is why we are constantly working on eliminating the risks posed by static electricity in all production processes and machinery. Protecting production equipment from earthquakes is another priority. When a tremor above a certain magnitude occurs, sensors on key machinery transmit a signal that activates
  • 10 U.S.operations The restructuring of In 1977, Takeda established a 50-50 partnership with Abbott Laboratories in the U.S. for research and development of new drugs. TAP Pharmaceutical Products Inc. was established in 1985 as a joint venture with Abbott in conjunction with the launch of the prostate cancer treatment Lupron (generic name: leuprorelin acetate). Since then TAP has greatly contributed to the growth of Takeda's ethical pharmaceutical business in the U.S. market through the expanding sales of Lupron Depot (sustained release formulation of leuprorelin acetate) and the peptic ulcer treatment Prevacid (generic name: lansoprazole). In April 2008, Takeda implemented the division of TAP upon agreement with Abbott and TAP became a wholly-owned subsidiary of Takeda. In July 2008, TAP was merged into Takeda Pharmaceuticals North America, Inc. (TPNA), and subsequently TAP's development function was integrated into Takeda Global Research & Development Center Inc. (TGRD). Through this restructuring, Takeda r
  • - 1 - SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) for the Fiscal Year Ending March 31, 2009 November 4, 2008 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: http://www.takeda.co.jp Representative: Yasuchika Hasegawa, President Contact: Hirofumi Inoue, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: November 14, 2008 Scheduled date of dividend payment commencement: December 1, 2008 1. Consolidated Financial Results (April 1 to September 30, 2008) for the Fiscal Year Ending March 31, 2009 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( million) change (%) Six mo
  • Takeda Pharmaceutical Company Limited (4502) SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) - 3 - [Descriptive Information and Financial Statements] 1. Descriptive Information on Consolidated Operating Results (1) Introduction In order to realize Takeda's goal of establishing itself as a "global pharmaceutical company", the Company has been working on the various strategies defined in the 20062010 Medium-term Plan. Of those strategies, with respect to "further strengthening ability to create new drugs", the Company has completed several important transactions this calendar year. Firstly, the acquisition of U.S.-based Millennium Pharmaceuticals Inc. (Millennium) provides Takeda Groupin addition to its own historical strength in research technology that inhibits cancer cell proliferationthe additional strength of Millennium's novel research technology based on inducing cancer cell apoptosis and also provides outstanding clinical development capabilities, both
  • 4 Message Kunio Takeda Chairman Yasuchika Hasegawa President To Our Stakeholders 5 Focused on Takeda's goal of "growth towards a worldclass pharmaceutical company," as set forth in the 2006-2010 Medium-Term Plan, and maximizing the advantages of our corporate philosophy of "Takeda-ism = Integrity," Takeda continues to implement a variety of strategies in our business operations. The foremost of those strategies is the "Enhancement of the R&D Pipeline," by achieving sustained growth through the discovery and development of in-house products and the strategic investment of resources in high priority research areas. Furthermore, Takeda continues to reinforce its R&D pipeline through alliancessuch as the in-licensing of products and technologiescorporate acquisitions and product life-cycle management to maximize the value of marketed products. Through these efforts, Takeda's pipeline now has greater depth and in December 2007, we successfully submitted two New Drug Applications (NDA) in the U.S. for the anti-dia
  • 54 Our Basic Stance toward Global Warming Prevention Takeda releases GHG into the air during each stage of our business operations, including the procurement of raw materials, manufacture, distribution and disposal, and hence takes the need to strive to reduce GHG emissions as a member of global society for granted. Takeda organized the energy conservation committee in 1974, following the first major oil shock, and followed subsequently by the steady implementation of energy conservation activities, which have helped reduce GHG emissions for over three decades. Takeda believes that promoting a further approach toward global warming prevention globally, while also sharing such actual achievements and knowhow, will be our challenges in future. Takeda has developed the 9th energy conservation program for the period 2006 - 2010 and our activities toward efficient energy use have been progressing. The 9th energy conservation program sets a target to reduce CO2 emissions by 40 percent (a reduction of 30 percent wi
  • Consolidated Financial Statements for the Fiscal Year Ended March 31, 2007 May 10, 2007 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya 1-1, Doshomachi 4-chome (First section of each) Chuo-ku, Osaka 540-8645, Japan Fukuoka, Sapporo URL: http://www.takeda.co.jp/ Code number: 4502 Representative: Yasuchika Hasegawa, President Contact: Toyoji Yoshida, Director, Corporate Communications Department Tel: +81-3-3278-2037 Scheduled date of annual general meeting of shareholders: June 28, 2007 Scheduled date of securities report submission: June 28, 2007 Scheduled date of dividend payment commencement: June 29, 2007 1. Consolidated Results for Fiscal 2006 (April 1, 2006 - March 31, 2007) (1) Sales and Income All amounts are rounded to the nearest million yen. Percentage figures represent changes from previous year. Net sales ( million)
  • CONTRIBUTESTOTHEHEALTHOFINDIVIDUALSWORLDWIDE ANNUAL R E P O R T 2005 Year ended March 31, 2005 Together with our corporate philosophy of Takeda-ism, our high ethical standards and strong sense of mission, developed over our 220-year history of knowing about the value of life, have become a vital part of our management today. TAKEDA-ISM We, the members of the Takeda Group, pledge to act with integrity at all times, especially when facing difficulties or challenges. "Integrity" refers to our compliance with the highest ethical standards, our fairness and honesty in conducting every activity, and our perseverance in pursuing the ideal forms for our operations and management. Through the demonstration of these qualities, we show our commitment to building trust and confidence in all the people around us, and our determination to continue to expand the business. These empower our progress in our global endeavors to fulfill our mission to "strive toward better health for individuals and progress in medicine by dev
  • 24 Review Of Operations And Financial Condition: Takeda Pharmaceutical Company Limited (Formerly Takeda Chemical Industries, Ltd.) and Subsidiaries Year ended March 31, 2004 (Fiscal 2003) As countries worldwide step up measures to hold down healthcare expenditures, while greater time and investments are required for development of new drugs, the ethical pharmaceuticals industry, which is Takeda's core business, is witnessing even more intense competition. In the United States, the world's largest pharmaceuticals market, double-digit growth in pharmaceuticals sales is unlikely to last much longer. One reason is that the expiration of patents on major drugs is often followed by rapid growth in sales of generic drugs. Also restraining growth are a variety of measures to limit the cost of drugs by the federal government, states, and insurance companies. Moreover, Medicare reforms, imports of less expensive drugs from Canada, and other events indicate that the United States is about to enter a period of fundament

Pages:[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]   Next

Page Top